To date total of twelve ADCs have been approved by the FDA namely Brentuximabvedotin, Gemtuzumabozogamicin, Enfortumabvedotin, Inotuzumabozogamicin, Moxetumomabpasudotox, Polatuzumabvedotin, Loncastuximabtesirine, Belantamabmafodotin, Trastuzumabderuxtecan, Sacituzumabgovitecan, Trastuzumabemtansine, and Tisotumabvedotin-tftv.